This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmerc ial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Abstract Objective: To investigate the associations of Graves' disease (GD) severity, autoimmunity and longitudinal liver enzyme changes with time in a cohort with well-characterized GD. Design: Retrospective cohort study. Patients: Patients diagnosed with Graves' disease, treated at Royal Prince Alfred Hospital Sydney, Adult Thyroid Clinic from 2000 to 2012 inclusive. Measurements: Inclusion criteria were patients with a complete set of TSH, FT4, FT3, liver enzymes and TSH receptor antibody (TRAb) results prior to commencement of thionamide therapy.
| MATERIAL S AND ME THODS
An audit of the Royal Prince Alfred Hospital Adult Thyroid Clinic, Sydney, Australia, database from 2000 to 2012 inclusive was undertaken to determine the liver enzyme profiles in patients with GD at baseline and after therapy. All patients aged 18 years or over with complete medical records, plus a blood TSH level below the lower limit of the normal laboratory reference range with an elevated free T3 and/or free T4 above the normal reference range at the time of GD diagnosis were included. Graves' disease was confirmed by an elevated TSH receptor antibody (TRAb) (>1.0 U/L) in serum at the time of diagnosis. 13 The TRAb measure was performed on either the B·R·A·H·M·S TRAK HUMAN RIA or the Roche Elecsys Anti-TSHR assay. Patients were categorized into one of seven ethnicity groups based on the self-reported heritage (adapted from Alharbi et al 14 ) .
The liver enzymes, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), ALP and gamma glutamyltransferase (GGT), prior to commencement of anti-thyroid medications, were tested on a standard biochemical autoanalyser platform. An abnormal liver profile was defined as one or more liver enzyme abnormality, outside the laboratory reported normal assay range, being present. A repeat liver enzyme profile of the same enzymes performed after patients achieved biochemical euthyroidism (defined as free T3 and free T4 in the normal range as well as blood TSH measure within the normal reference range), was included for analysis. We included any patients with no reported known history of active liver disease or being on hepatotoxic medications. The cohort included one patient with a history of chronic hepatitis B. This patient had an abnormal liver enzyme profile on initial presentation and was not receiving antiviral therapy; the liver enzyme abnormality resolved when thyroid hormone normalized. One patient only was excluded from the study as having hepatitis C receiving interferon alpha treatment. There was no history of alcohol dependence or heavy alcohol usage in any patients in the cohort.
Considering the non-linear reading of TRAb, FT3 and FT4 results at high levels, the TRAb level was categorized into mild, moderate and severe elevations, as TRAb ≤ 10 IU/L, TRAb = 10.1-20 and TRAb > 20,
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| RE SULTS
There were 146 patients diagnosed with Graves' disease with a complete medical record and blood tests as described, between the years 2000 and 2012 (Table 1) . Eighty-two per cent of the cohort were female, with mean age ± SD for GD diagnosis of 35.2 ± 11.5 years, and median 33 years. Thirty-nine per cent of the entire cohort had a family history of thyroid disorder and 64% were lifelong non-smokers. The predominant ethnic background was East Asian (48%), followed by European (40%). Apart from a trend towards significance (P = 0.06) for mean age of GD diagnosis between patients with normal and abnormal liver function results, there were no other patient clinical characteristics associated with an abnormal liver enzyme profile (Table 1) . Overall, 75% of patients received carbimazole and 25% received PTU.
Among the 146 patients, 69 (47%) had at least one abnormal liver enzyme. Among the liver enzymes, the GGT was most frequent abnormality, in 74% of patients, followed by ALT (56.5%), ALP (39.1%) and AST (29.0%; Figure 1A ). In individuals with East Asian background, GGT and ALP abnormality were found in 32% and 25% of the liver enzyme abnormalities, whereas 48% and 9% of those liver enzyme abnormalities, respectively, were noted among the European descendants ( Figure 1B ).
By logistic regression analyses, severely elevated TRAb
(>20 IU/L) was significantly associated with the presence of one or more liver enzyme abnormality (P = 0.008; Table 2 ). Free T3 and free T4 were also independently associated with the presence of abnormal liver enzymes. Both severely and moderately elevated FT3 were significantly associated with at least one abnormal liver enzyme (OR = 7.32, P < 0.001 and OR 8.57, P < 0.001 respectively; Table 2 ). Having moderately elevated FT4 was significantly associated with an abnormal liver enzyme profile (Odds Ratio 2.65, P = 0.01), whereas severely elevated FT4 carried a much greater odds ratio, of 10.9 (P < 0.001; Table 2 ). However, neither TRAb, nor FT4 or FT3 was associated with any specific individual liver enzyme elevation.
When combining the thyroid hormones (FT3 and FT4) and TSH receptor antibody (TRAb) results in a multivariable analysis, the TRAb level was no longer associated with abnormal liver enzymes (Table 3 ). In contrast, moderately elevated FT3 (P = 0.002) and
severely elevated FT3 (P = 0.02), as well as severely elevated FT4
(P = 0.01), remained significantly associated with the presence of any liver enzyme abnormality. By multivariate logistic regression analy- have reported data combining all hyperthyroid diagnoses (Table 4 ).
In this Graves' disease-specific cohort, we found 47% of patients presented with at least one abnormal liver enzyme. The frequency approximates data reported in the other GD-specific studies, where 35%-70% of study participants had at least one liver enzyme abnormality. 2, 3, 12 Among the n = 69 patients with any liver enzyme abnormality in the current series, 74% had a GGT abnormality, followed by ALT (56.5%), ALP (39.1%) and AST (29%; Figure 1A ). The distribution of liver enzyme abnormalities in this cohort was notably different from other previously reported GD-specific studies and other hyperthyroid studies (Table 4 ). Most studies reported ALP as the most commonly elevated liver enzyme. In our study, among individuals with East Asian background, GGT and ALP abnormalities were found in 32% and 25% of the liver enzyme abnormalities, whereas 48% and 9% of those liver enzyme abnormalities, respectively, were noted among the European descendants ( Figure 1B) . The AST and ALT distributions, however, were similar between these two ethnic subgroups. Interestingly, there appears to be an ethnic difference between cases of GD with a liver enzyme abnormality. China with over 200 participants with GD 3,12 demonstrated ALT and ALP as the most frequently detected liver enzyme abnormalities, compared with ALP predominantly in other studies. 1,4,5 The cause for this difference is unclear and as liver and bone ALP isoenzymes were not differentiated in those studies, and it is unclear whether the ALP elevations reported were contributed to by bone-derived ALP.
Two large studies in
Our study did not specifically exclude patients with potential liver function abnormalities related to hepatitis history, alcohol use or iatrogenic causes; however, the longitudinal data demonstrate that when patients achieved a hormonal euthyroid state, only 11%
of individuals with initial liver enzyme abnormalities had any persistent abnormality, which was predominantly in the ALP and GGT.
This longitudinal data provide evidence that the abnormal liver enzyme profile at acute hyperthyroid presentation is likely due to the hyperthyroid state, and the persistent cholestatic liver enzyme abnormality, albeit in a minority of cases, may in some cases be related to ongoing use of thionamides, as observed by other studies, 4,7 even though the enzyme abnormalities in the current series were present before thionamides had been commenced, or possibly in the case of ALP may be bone-derived.
The univariate analysis identified FT3, FT4 and TRAb as three independent risk factors associated with a liver enzyme abnormality at diagnosis of GD (Table 2) whereas the multivariate logistic regression analysis of FT3, FT4 and TRAB demonstrated the elevation in liver enzymes was associated more strongly with FT3 and FT4 than TRAb (Table 3 ). In contrast, the multivariate analysis in the largest GD-specific study concluded that only FT4 and TRAb are strongly associated with hepatic dysfunction. 12 The average FT4 level reported by Zhang was 85.7 pmol/L (normal range: 12-22 pmol/L),
which is approximately twice the average FT4 level in our cohort with similar reference range. At high FT4 and FT3 levels, many commercial immunoassays do not follow a linear correlation and this may not be addressed by logistic transformation of the data, 15, 16 hence our rationale to categorize TRAb, FT3, FT4 elevation in our analysis.
In addition, FT3 and FT4 levels were to some degree independently correlated with the serum TRAb level (Table S1) Strengths of the current research are that GD was carefully defined in the cohort studied, liver enzymes were measured before any treatment of the hyperthyroidism, and follow-up liver enzymes were documented as GD was treated. Relative study weaknesses include the retrospective nature of the cohort limiting total patient numbers with complete data and no ALP isoenzyme measures, some loss to follow-up of patients and the absence of TSI measures in preference or in addition to the clinical TRAb measure. Despite these shortcomings, we believe that the work adds valuable information about liver enzyme frequency and sub-type, and resolution in GD, which aids clinical interpretation in patients with GD and liver enzyme abnormalities.
In conclusion, our data identified the liver enzyme abnormality patterns and the normalization of liver enzymes in treated Graves' disease, and that the enzyme abnormality most commonly present was GGT. The elevation in liver enzymes was associated more strongly with FT3 and FT4 than TRAb. With the observation that liver enzyme abnormalities are common in untreated GD and that they may secondarily be affected by thionamide therapy in GD, we agree with the ATA 2016 guideline comment that baseline liver function enzyme tests should be considered before initiation of anti-thyroid medication. 13 In addition, we assert that patients should be assured that liver enzyme abnormalities at diagnosis will most likely settle in time, with appropriate medical therapy as the patient becomes biochemically euthyroid.
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